Kintara Therapeutics, Inc. (KTRA)
| Market Cap | 42.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.91M |
| Shares Out | 24.85M |
| EPS (ttm) | -2.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $1.39 |
| Previous Close | $1.57 |
| Change ($) | -0.18 |
| Change (%) | -11.46% |
| Day's Open | 1.53 |
| Day's Range | 1.38 - 1.54 |
| Day's Volume | 406,826 |
| 52-Week Range | 0.50 - 3.35 |
Kintara Therapeutics Inc (NASDAQ:KTRA) has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme (GBM), which continue to demonstrate its pote...
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are faili...
Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021. Kintara Therapeutics, Inc. (NASDAQ: KTRA) a biopharm...
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...
Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) has hired cancer expert Dr Mario Lacouture to its Cutaneous Metastatic Breast Cancer (CMBC)-focused scientific advisory board. It comes as the company p...
Kintara Therapeutics Inc (NASDAQ: KTRA) has enrolled the final patient in the recurrent arm of its ongoing Phase 2 study evaluating VAL-083 for glioblastoma multiforme, the most aggressive form of brain...
Kintara Therapeutics Inc (NASDAQ:KTRA) announced Wednesday that it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme (GBM) study of its VAL-083 ...
Kintara Therapeutics Inc (NASDAQ:KTRA), the cancer-focused biopharma, said it has enough cash to fund its planned operations into the fourth quarter of calendar 2021, as the company posted its second-qu...
Kintara Therapeutics (NASDAQ:KTRA) is currently down 7.64% to a price of $2.46. The stock's volume is currently 77.04 thousand, which is roughly 4.66% of its recent 30-day volume average of 1.66 million.
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...
SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has entered into definitiv...
SAN DIEGO, Aug. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that it has regained compliance w...
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b... [Read more...]
| Industry Biotechnology | Founded 2009 |
| CEO Saiid Zarrabian | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol KTRA |